Related Experiment Video
Updated: Mar 14, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Industry update: the latest developments in the field of therapeutic delivery, December 2025
1Department of Pharmacy, University of Huddersfield, Queensgate, UK.
Abstract:
There was significant activity through December 2025 in respect of advancing new weight management therapies, with the first approved orally GLP-1 receptor agonist becoming available from Novo Nordisk, but with late stage and early phase assets being pursued by Lilly, Structure Therapeutics, Pfizer/YaoPharma, and Zealand/OTR. Cell and gene therapy for rare diseases was highlighted in new product approvals for Fondazione Telethon, Novartis, and positive clinical trial findings for Capricor Therapeutics, Kyverna Therapeutics, Encoded Therapeutics and Kite. Other rare disease therapies were the subject of announcements around deals and collaborations from BioMarin/Amicus, Mirum/Bluejay, Shionogi/Tanabe, Regeneron/Tessera, and positive clinical trial outcomes from Belie Bio. Novel delivery approaches progressed with the approval of Milestone's nasal spray formulation of a calcium channel blocker for PSVT and clinical trial progress for a doxorubicin microneedle array patch from Medicus for basal skin carcinoma.
Related Concept Videos
Modified-Release Drug Delivery Systems: Overview
Transdermal Drug Delivery Systems
Modified-Release Drug Delivery Systems: Site-Targeted
Modified-Release Drug Delivery Systems: Rate-Programmed II
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Site-Targeted Drug Delivery Systems: Polymeric Carriers

